Clinical trial · Interventional
flt3L in Treating Patients With Acute Myeloid Leukemia
A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission
NCT00006223CI-TRIAL-00011017completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs such as flt3L may stimulate a person's immune system and help kill cancer cells. It is not yet known if flt3L is effective in treating acute myeloid leukemia. PURPOSE: Randomized phase III trial to determine the effectiveness of flt3L in treating patients who have acute myeloid leukemia that is in remission.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| recombinant flt3 ligand | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Diagnosis of acute myeloid leukemia in first, second, third, or subsequent complete remission (CR)
* Must be at least 60 years of age if first CR
* Must have had histological proof (from bone marrow aspirate, smears, or touch preps of marrow biopsy) of one of the following prior to achieving CR:
* Acute myeloblastic leukemia (M0, M1, M2)
* Acute promyelocytic leukemia (M3)
* Acute myelomonocytic leukemia (M4)
* Acute monocytic leukemia (M5)
* Acute erythroleukemia (M6)
* Acute megakaryocytic leukemia (M7)
* Refractory anemia with excess blasts in transformation
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* ECOG 0-2
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Bilirubin less than 3 times upper limit of normal (ULN)
* SGOT less than 3 times ULN
Renal:
* Creatinine less than 2 mg/dL
Cardiovascular:
* No clinically significant active cardiac disease
Pulmonary:
* No clinically significant active pulmonary disease
Other:
* Not pregnant or nursing
* Fertile patients must use effective contraception
* No uncontrolled or active autoimmune disease
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Prior autologous bone marrow transplantation (BMT) allowed
* No prior allogeneic BMT
* Other prior immunotherapy allowed if not received during the most recent treatment
Chemotherapy:
* Not specified
Endocrine therapy:
* Not specified
Radiotherapy:
* Not specified
Surgery:
* Not specifiedReferences
Publications (0)
Data not yet available
No reference posted for this study.